Phenomenex Clarity® OTX™ Receives R&D 100 Award for Innovation
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Phenomenex, Inc. has announced that the company has received a 2010 R&D 100 award for its Clarity OTX oligonucleotide extraction kit. This SPE (solid phase extraction) method is an advanced approach to the isolation of RNA and DNA-based therapeutics and their metabolites from biological matrices.
The awards, determined by an independent judging panel and the editors of R&D Magazine, recognize the 100 most technologically significant products introduced during the past year. According to the magazine, the awards are widely regarded as the "Oscars of Innovation."
2010 is the fifth consecutive year in which Phenomenex has received this award, and two of the company's products were recognized. Another award went to the company's Kinetex® core-shell HPLC column technology.
According to bioseparations product manager Michael McGinley, "Clarity OTX removes a major roadblock in oligonucleotide drug development and there is nothing like it on the market. It's a game-changing innovation."
Unlike previous oligonucleotide therapeutic isolation techniques that use labor-intensive, low-throughput, liquid/liquid extraction methods, Clarity OTX isolates oligonucleotide therapeutics and their metabolites in just 15 minutes. Clarity OTX extraction kits effectively remove cell debris that can mask the oligo therapeutic or metabolite of interest and interfere with low-level MS detection.
"The R&D 100 Awards have always represented some of the most innovative concepts to reach the marketplace in the past year. 2010 is no exception, and we had a particularly strong field of entries for the judges to evaluate," said Rita Peters, editorial director of R&D Magazine.
R&D 100 award winners will be recognized at the annual banquet on November 11, 2010 in Orlando, Fla.
The awards, determined by an independent judging panel and the editors of R&D Magazine, recognize the 100 most technologically significant products introduced during the past year. According to the magazine, the awards are widely regarded as the "Oscars of Innovation."
2010 is the fifth consecutive year in which Phenomenex has received this award, and two of the company's products were recognized. Another award went to the company's Kinetex® core-shell HPLC column technology.
According to bioseparations product manager Michael McGinley, "Clarity OTX removes a major roadblock in oligonucleotide drug development and there is nothing like it on the market. It's a game-changing innovation."
Unlike previous oligonucleotide therapeutic isolation techniques that use labor-intensive, low-throughput, liquid/liquid extraction methods, Clarity OTX isolates oligonucleotide therapeutics and their metabolites in just 15 minutes. Clarity OTX extraction kits effectively remove cell debris that can mask the oligo therapeutic or metabolite of interest and interfere with low-level MS detection.
"The R&D 100 Awards have always represented some of the most innovative concepts to reach the marketplace in the past year. 2010 is no exception, and we had a particularly strong field of entries for the judges to evaluate," said Rita Peters, editorial director of R&D Magazine.
R&D 100 award winners will be recognized at the annual banquet on November 11, 2010 in Orlando, Fla.
